Literature DB >> 31532354

Physical and chemical characterization of McIntyre Powder: An aluminum dust inhaled by miners to combat silicosis.

Andrew Zarnke1, Pat E Rasmussen2, Marie-Odile David3, Housam Eidi4, Konnor Kennedy1, Kevin Hedges5, Todd Irick5, Christopher Thome6, Jake Pirkkanen1, Douglas Boreham1,7.   

Abstract

McIntyre Powder (MP) is a finely ground aluminum powder that was used between 1943 and 1979 as a prophylaxis for silicosis. Silicosis is a chronic lung disease caused by the inhalation of crystalline silica dust and was prevalent in the Canadian mining industry during this time period. The McIntyre Research Foundation developed, patented, and produced the MP and distributed it to licensees in Canada, the United States, Mexico, Chile, Belgian Congo, and Western Australia. In the province of Ontario, Canada it is estimated that at least 27,500 miners between 1943 and 1979 were exposed to MP. The present study was undertaken to examine the chemical and physical characteristics of two variations of MP (light grey and black). Chemical analyses (using X-ray Fluorescence and Inductively Coupled Plasma approaches) indicate that the black MP contains significantly higher concentrations of aluminum and metal impurities than the light grey MP (p < 0.001). X-ray diffractometry shows that while aluminum hydroxide dominates the aluminum speciation in both variations, the higher total aluminum content in the black MP is attributable to a greater proportion of elemental aluminum. Physical characterization (using electron microscopy, light microscopy, and dynamic light scattering) indicates that the light grey MP consists of particles ranging from 5 nm to 5 µm in diameter. Atomic Force Microscopy shows that the light grey MP particles in the nanoparticle range (<100 nm) have a mode between 5 and 10 nm. Consequently, it is possible that inhaled smaller MP nanoparticles may be transported via blood and lymph fluid circulation to many different organs including the brain. It is also possible for inhaled larger MP particles to deposit onto lung tissue and for potential health effects to arise from inflammatory responses through immune activation. This MP characterization will provide crucial data to help inform future toxicological, epidemiological, and biological studies of any long-term effects related to the inhalation of aluminum dust and nanomaterials.

Entities:  

Keywords:  Aluminum; McIntyre Powder; aluminum inhalation; nanoparticles; occupational exposures; particle characterization

Year:  2019        PMID: 31532354     DOI: 10.1080/15459624.2019.1657581

Source DB:  PubMed          Journal:  J Occup Environ Hyg        ISSN: 1545-9624            Impact factor:   2.155


  4 in total

1.  Aluminum dust exposure and risk of neurodegenerative diseases in a cohort of male miners in Ontario, Canada.

Authors:  Xiaoke Zeng; Jill Macleod; Colin Berriault; Nathan L DeBono; Victoria H Arrandale; Anne M Harris; Paul A Demers
Journal:  Scand J Work Environ Health       Date:  2021-09-30       Impact factor: 5.024

2.  Compositional and structural analysis of engineered stones and inorganic particles in silicotic nodules of exposed workers.

Authors:  Antonio León-Jiménez; José M Mánuel; Marcial García-Rojo; Marina G Pintado-Herrera; José Antonio López-López; Antonio Hidalgo-Molina; Rafael García; Pedro Muriel-Cueto; Nieves Maira-González; Daniel Del Castillo-Otero; Francisco M Morales
Journal:  Part Fibre Toxicol       Date:  2021-11-22       Impact factor: 9.400

Review 3.  McIntyre Powder and its potential contributions to cardiovascular disease risk: A literature review through the McIntyre Powder historical lens.

Authors:  Andrew Zarnke; Christine Oliver; Sandra Dorman
Journal:  Am J Ind Med       Date:  2022-07-21       Impact factor: 3.079

4.  Trading One Risk for Another: Consequences of the Unauthenticated Treatment and Prevention of Silicosis in Ontario Miners in the McIntyre Powder Aluminum Inhalation Program.

Authors:  Janice Martell; Tee L Guidotti
Journal:  New Solut       Date:  2021-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.